Biocentury: Regeneron using Interleukin Antibody Receptors for Asthma … – OneMedPlace (blog)

Biocentury: Regeneron using Interleukin Antibody Receptors for Asthma
OneMedPlace (blog)
An estimated 25 million Americans suffer from Asthma, but current medications such as inhalers have been deemed ineffective for 10-20% of its users. Regneron (REGN) and Sanofi (SAN) have partnered to crease a new Asthma drug, Dupilumab. In their
Clearing The Air On The Sanofi-Regeneron Asthma Drug TrialSeeking Alpha

all 2 news articles »

View full post on asthma – Google News

Leave a Reply

Your email address will not be published. Required fields are marked *

This site uses Akismet to reduce spam. Learn how your comment data is processed.